KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Current Leases (2021 - 2025)

Castle Biosciences (CSTL) has disclosed Current Leases for 5 consecutive years, with $1.3 million as the latest value for Q4 2025.

  • Quarterly Current Leases fell 20.42% to $1.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.3 million through Dec 2025, down 20.42% year-over-year, with the annual reading at $1.3 million for FY2025, 20.42% down from the prior year.
  • Current Leases hit $1.3 million in Q4 2025 for Castle Biosciences, down from $1.4 million in the prior quarter.
  • In the past five years, Current Leases ranged from a high of $2.0 million in Q2 2023 to a low of $1.1 million in Q3 2023.
  • Historically, Current Leases has averaged $1.4 million across 5 years, with a median of $1.4 million in 2025.
  • Biggest five-year swings in Current Leases: surged 62.35% in 2023 and later plummeted 37.64% in 2024.
  • Year by year, Current Leases stood at $1.2 million in 2021, then skyrocketed by 50.72% to $1.8 million in 2022, then crashed by 36.02% to $1.1 million in 2023, then skyrocketed by 46.44% to $1.7 million in 2024, then fell by 20.42% to $1.3 million in 2025.
  • Business Quant data shows Current Leases for CSTL at $1.3 million in Q4 2025, $1.4 million in Q3 2025, and $1.6 million in Q2 2025.